|
The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Alexander Rheinhard Siebenhuener |
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Lilly; PharmaMar |
Consulting or Advisory Role - Eisai; Lilly |
Travel, Accommodations, Expenses - Amgen; PharmaMar; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Celgene (I) |
Consulting or Advisory Role - Celgene (Inst); Debiopharm Group (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); UCB (Inst) |
Travel, Accommodations, Expenses - Novocure |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |